Philips Stock Plummets as FDA Continues to Reject Recall Efforts

The U.S. Food and Drug Administration (FDA) has expressed dissatisfaction with Dutch healthcare technology company Philips' handling of a major product recall, stating that additional risk testing is necessary. Philips' shares fell over 9% in response to the FDA's update. The recall, which has been ongoing since 2021, involves millions of sleep apnea and respiratory devices that used a foam material that could degrade and cause harm. Philips has conducted testing but has agreed to the FDA's call for more. The company has suffered significant market valuation losses due to the recall and is still facing personal injury claims and an investigation by the U.S. Department of Justice.